Key facts
as of Sep 2026- It has raised $960K across 1 recorded rounds; the latest was Seed Round ($957K) in Dec 2024.
- 1 institutional filer reports fund marks on AstralBio across 11 filings.
- AstralBio has filed 1 Form D with the SEC, most recently Dec 2024 ($957K sold to 2 investors).
- Status: Privately Held (backing).
PA Mark — composite indicative price
LOW confidence~$16per share
as of Sep 2026 · the exact daily mark is a member feature
Free account
See the evidence behind this price
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for AstralBio
Create free account
No card required
Recorded secondary trades
No prints on record
No secondary trades in AstralBio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Pro members can request priority coverage with a 48-hour turnaround.
Institutional fund marks
1 filers · latest Oct 20251 SEC-registered fund reported 11 fair-value marks on AstralBio between Apr 2025 and Oct 2025. Filer-level marks and implied $/share are available to Pro members.
Funding rounds
1 roundsAbout AstralBio
Operator of a biotechnology company intended to develop medicines to treat cardiometabolic and immune-mediated diseases. The company's medicines are created using artificial intelligence systems to accelerate the progression of novel therapeutic targets, enabling clients to transform patient care.
- Sector
- Healthcare
- HQ
- Boston, MA, United States
- Founded
- 2023
- Website
- astralbio.com/
- Ownership
- Privately Held (backing)